EUS-guided RFA for Solid Abdominal Neoplasms

Status Recruiting

Clinical Trial Summary

Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of solid abdominal neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic cancers. The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid abdominal neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid abdominal neoplasms.

Clinical Trial Description

RFA causes tissue destruction through the application of a high frequency alternating current, generating local temperatures above 60°C and leading to coagulative necrosis. The technique has been widely used in many solid organ tumours and has been shown to result in 5-year survival rates comparable to surgery. The technique is currently the standard therapy in hepatocellular carcinoma and colorectal pulmonary metastasis particular in patients that are not suitable for surgery. The current study would be a multi-center prospective study involving four high volume international institutions. Consecutive patients suffering from solid neoplasms of the liver, stomach and adrenals would be recruited. EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea). The primary outcome would be the overall adverse events rate. Secondary outcomes include mortality, technical success rate, completion ablation rate, 1 & 3 year overall and disease-free survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03221335
Study type	Interventional
Source	Chinese University of Hong Kong
Contact	Anthony YB Teoh, Professor
Phone	26322956
Email	anthonyteoh@surgery.cuhk.edu.hk
Status	Recruiting
Phase	N/A
Start date	May 2016
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06026800` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms	Phase 1
Recruiting	`NCT06026774` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms	Phase 1
Recruiting	`NCT06019702` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms	Phase 1
Completed	`NCT02909452` - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT05602935` - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study	Phase 2
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Completed	`NCT03717298` - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma	Phase 2
Recruiting	`NCT05322486` - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting	`NCT04556344` - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer	N/A
Terminated	`NCT03306693` - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers	N/A
Active, not recruiting	`NCT01037049` - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks	Phase 2
Recruiting	`NCT02208804` - Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization	Phase 2/Phase 3
Completed	`NCT04080843` - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients	Phase 2
Recruiting	`NCT03303495` - A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC	Phase 3
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Recruiting	`NCT03271255` - Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)	Phase 2
Recruiting	`NCT02487017` - DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT01556815` - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT04949282` - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Completed	`NCT01964430` - Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)	Phase 3